BioSante Pharmaceuticals, Inc. (BPAX)

[dgras0007]

From the yahoo board -
...listen very carefully to the Q&A session; the Libigel story is NOT over yet!!!

Also, the company's CFO stated that the expected cash balance at the end of 2011 to be $56 million and the estimated monthly cash flow in 2012 to be significantly less than $3.2 million per month. So BPAX may not be in too bad of a finanacial position; possibly not even require a stock issue until late 2012.

During the Q&A session, BPAX was asked about what sort of data in the results would they be reviewing and the answer was basically, to "look at subsets of the data"! I believe that this is where LibiGel will make a comeback. Listen carefully to the answer to this question. As per Simes; "the results were shocking to us"!!! Simes also stressed on several occassions the strong possibility of the "Placebo effect"! That's why I believe that a continued data review on subsets of data is going to come back showing something very interesting.

Again, lots of discussion around the
"placebo effect" issue! As Simes noted, "Why did the placebo do so well" he also stressed that the placeb "did OVERWHELMINGLY WELL"! http://www.skepdic.com/placebo.html

Also, Simes indicated, "cash is more than sufficient" to continue forward with the Libigel safety trial! Ask yourself why would BPAX continue spending near $3 million per month on the safety trial and othe LibiGel NDA related expenses if they weren't thinking that there is something else going on with these recent efficacy results???